-
VOLUNTARY ANNOUNCEMENT - B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093 RECEIVED FDA BREAKTHROUGH THERAPY DESIGNATION2024-08-20
-
VOLUNTARY ANNOUNCEMENT - THE FOURTH NEW DRUG APPLICATION OF AMEILE (AUMOLERTINIB MESILATE TABLETS) WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION2024-08-19
-
DATE OF BOARD MEETING2024-08-15
-
VOLUNTARY ANNOUNCEMENT - LICENSING AGREEMENT WITH LUPENG PHARMA2024-08-08
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 20242024-08-01
-
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION OF AMEILE FOR THE ADJUVANT TREATMENT OF EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION2024-07-19
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 20242024-07-02
-
GRANT OF RESTRICTED SHARE UNITS UNDER THE POST-IPO RSU SCHEME2024-06-27
-
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON THURSDAY, JUNE 13, 20242024-06-13
-
ADJUSTMENT TO CONVERSION PRICE OF THE CONVERTIBLE BONDS2024-06-13
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 20242024-06-03
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 20242024-05-02
